A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Summary

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug

Timeline

Start

2023-03-15

Primary completion

2025-02-10

Completion

2025-02-10

Outcome

Outcome not reported

Stopped: “Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis demonstrated that the depth and consistency in B Cell depletion required to measure success was insufficient.”

Drugs

Indications